| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Dec'17 |
|---|---|---|---|---|---|---|
ASSETS | ||||||
CURRENT ASSETS | ||||||
Cash and cash equivalents | ||||||
468 | 2,352 | 3,768 | 5,813 | 8,586 | 6,707 | 7,375 |
Accounts and grants receivable, net | ||||||
366 | 363 | 234 | 208 | 206 | 131 | 107 |
Prepaid expenses and other current assets | ||||||
1,238 | 1,339 | 688 | 659 | 856 | 1,015 | 111 |
Total current assets | ||||||
2,072 | 4,054 | 4,690 | 6,680 | 9,648 | 7,853 | 7,593 |
Property and equipment, net | ||||||
898 | 1,126 | 1,010 | 951 | 84 | 90 | 129 |
Deposits and other long-term assets | ||||||
111 | 111 | 193 | 196 | 19 | 19 | 35 |
Intangible assets, net | ||||||
2,011 | 2,151 | 2,290 | 2,430 | 2,570 | 2,709 | 1,874 |
TOTAL ASSETS | ||||||
5,092 | 7,442 | 8,183 | 10,257 | 12,321 | 10,671 | 9,631 |
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||
CURRENT LIABILITIES | ||||||
Accounts payable and accrued liabilities | ||||||
2,184 | 1,582 | 1,757 | 1,584 | 1,316 | 1,366 | 768 |
Loan due to Juvenescence, net of debt issuance cost | ||||||
1,767 | - | 319 | 62 | 140 | 132 | 210 |
Related party payables, net | ||||||
181 | 64 | - | - | - | - | - |
Deferred revenues | ||||||
407 | 283 | 219 | 266 | 361 | 317 | 180 |
Right-of-use lease liability | ||||||
325 | 428 | 417 | 407 | - | - | - |
Insurance premium liability and other current liabilities | ||||||
603 | 940 | 195 | 310 | - | 625 | - |
Total current liabilities | ||||||
5,467 | 3,297 | 2,907 | 2,629 | - | 2,440 | - |
Loan due to Juvenescence, net of debt issuance cost | ||||||
- | 1,528 | 191 | - | - | - | - |
Right-of-use lease liability, net of current portion and other noncurrent liabilities | ||||||
- | - | 142 | - | - | - | - |
Right-of-use lease liability, net of current portion | ||||||
- | - | - | 221 | - | - | - |
Other current liabilities | ||||||
- | - | - | - | 477 | - | 154 |
TOTAL LIABILITIES | ||||||
5,467 | 4,825 | 3,240 | 2,850 | 2,294 | 2,440 | 1,312 |
STOCKHOLDERS' EQUITY (DEFICIT) | ||||||
Common stock, $0.0001 par value, 100,000 shares authorized; 37,656 and 37,649 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively | ||||||
4 | 4 | 4 | 4 | 4 | 4 | 3 |
Additional paid-in capital | ||||||
88,608 | 88,353 | 87,758 | 86,975 | 86,480 | 81,499 | 73,761 |
Accumulated other comprehensive income | ||||||
44 | 69 | 74 | 44 | 24 | -2 | 68 |
Accumulated deficit | ||||||
-89,395 | -86,208 | -83,497 | -80,276 | -77,187 | -74,054 | -66,552 |
AgeX Therapeutics, Inc. stockholders' equity (deficit) | ||||||
-739 | 2,218 | 4,339 | 6,747 | 9,321 | 7,447 | 7,280 |
Noncontrolling interest | ||||||
364 | 399 | 604 | 660 | 706 | 784 | 1,039 |
Total stockholders' equity (deficit) | ||||||
-375 | 2,617 | 4,943 | 7,407 | 10,027 | 8,231 | 8,319 |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||
5,092 | 7,442 | 8,183 | 10,257 | 12,321 | 10,671 | 9,631 |